ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0955 • ACR Convergence 2020

    Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)

    Rohit Aggarwal1, Christina Charles-Schoeman2, Joachim Schessl3, Zsuzsanna Bata-Csorgo4, Mazen Dimachkie5, Zoltan Griger6, Sergey Moiseev7, Chester Oddis8, Elena Schiopu9, Jiří Vencovský10, Beckmann Irene11, Clodi Elisabeth11, Todd Levine12 and and the ProDERM Investigators13, 1University of Pittsburgh, Pittsburgh, PA, 2University of California, Los Angeles, Los Angeles, CA, 3Städtisches Klinikum Karlsruhe, Karlsruhe, Germany, 4University of Szeged, Faculty of Medicine, Szeged, Hungary, 5Univeristy of Kansas, Medical Center, Kansas City, KS, 6University of Debrecen, Debrecen, Hungary, 7First Moscow State Medical University, Moscow, Russia, 8Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 9Michigan Medicine, Ann Arbor, MI, 10Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 11Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria, 12Phoenix Neurological Associates, LTD, Phoenix, AZ, 13Different Institutions in several countries, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…
  • Abstract Number: 1065 • ACR Convergence 2020

    Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis

    Adarsh Ravishankar1, Daisy Yan2, Christina Bax3, Josef Symon Concha2, Bridget Shields4, Lisa Pappas-Taffer4, Rui Feng5, Joyce Okawa4 and Victoria Werth2, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Philadelphia

    Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
  • Abstract Number: 1397 • ACR Convergence 2020

    Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort

    Smriti Prasad1, Samantha Black2, Shivani Sharma3 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2The University of Texas Southwestern Medical Center, Dallas, TX, 3University of Texas Southwestern, Dallas, TX

    Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
  • Abstract Number: 1560 • ACR Convergence 2020

    Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry

    Laila Abbas1, Jennifer Day2 and Heidi Jacobe3, 1UT Southwestern Medical Center, Dallas, TX, 2University of Colorado, Denver, CO, 3University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…
  • Abstract Number: 1820 • ACR Convergence 2020

    Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity

    Margaret Markiewicz1, Dayvia Russell2 and Jim Oates1, 1Medical University of South Carolina, Charleston, SC, Charleston, SC, 2.Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
  • Abstract Number: PP07 • ACR Convergence 2020

    Improving Communication with My Physician Drastically Improved My Health

    Whitney Carter1, 1Lupus and Allied Diseases Association, Inc., Pleasanton, CA

    Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…
  • Abstract Number: 0086 • ACR Convergence 2020

    Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers

    Bina Kassamali1, Anastasiya Muntyanu2, Ruth Ann Vleugels3 and Avery LaChance3, 1Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2McGill University, Montreal, QC, Canada, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by induration progressing proximally along the upper and lower extremities. Given the…
  • Abstract Number: 0451 • ACR Convergence 2020

    Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis

    Sophia Verspohl1, Tobias Holderried1, Charlotte Behning2, Peter Brossart1 and Valentin Schaefer3, 1Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
  • Abstract Number: 0627 • ACR Convergence 2020

    Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series

    Timothy Buckey1, Mali Jurkowski1, Kevin Lu2, Roberto Caricchio2 and Aruni Jayatilleke2, 1Temple University, Philadelphia, PA, 2Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    Background/Purpose: People with rheumatic diseases may be at high risk for poor outcomes related to COVID-19; on the other hand, immunomodulatory medications are used as…
  • Abstract Number: 0975 • ACR Convergence 2020

    Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage

    Xinghao Wang1, Luz Blanco2, Carmelo Carmona-Rivera3, Shuichiro Nakabo3, Hege Pedersen4, Zu-Xi Yu5 and Mariana Kaplan3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, Canton, MI, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, 5National Heart, Lung, and Blood Institute Pathology Core, Bethesda

    Background/Purpose: Gasdermin D (GSDMD) is the key executioner of the inflammatory cell death mechanism pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of…
  • Abstract Number: 1076 • ACR Convergence 2020

    Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom

    Lois Bolko1, Kevin Didier2, Jean-Hugues Salmon1, Makoto Miyara3, Segolene Toquet2, Amelie Servettaz2, Yves Allenbach3, Olivier Benveniste4 and Baptiste Hervier5, 1Maison Blanche Hospital, Reims, Champagne-Ardenne, France, 2Robert Debre Hospital, Reims, Champagne-Ardenne, France, 3Sorbonne Université, Paris, Ile-de-France, France, 4Sorbonne Université, paris, France, 5Saint-Louis Hospital, Paris, Ile-de-France, France

    Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
  • Abstract Number: 1398 • ACR Convergence 2020

    The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort

    Sabrina Elliott1, Duncan Moore2 and Virginia Steen2, 1MedStar Georgetown Hospital, Alexandria, VA, 2Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC

    Background/Purpose: Systemic Sclerosis (SSc) patients with an isolated nucleolar patterned ANA (NUC ANA) make up about 15% of the SSc population, although the specific nucleolar…
  • Abstract Number: 1566 • ACR Convergence 2020

    Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution

    Christina Boutsicaris1, Angelo Ciliberti2, Elizabeth Lockerman1, Faizah Siddique3 and Rochella Ostrowski1, 1Loyola University Medical Center, Maywood, IL, 2Loyola University Medical Center, Oak Park, IL, 3Loyola University Medical Center, Lombard, IL

    Background/Purpose: Immune checkpoint inhibitors (ICI) have improved outcomes for many types of cancer, but the therapy is known to cause immune-related adverse events (IRAE). ICI…
  • Abstract Number: 1825 • ACR Convergence 2020

    Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases

    Gemma Cramarossa1, Hsin-Yen Liu2 and Janet Pope3, 1Western University, Kleinburg, ON, Canada, 2Western University, London, ON, Canada, 3Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada

    Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
  • Abstract Number: PP10 • ACR Convergence 2020

    Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope

    Isabel Bautista1 and Michael Linn2, 1Relapsing Polychondritis Foundation, Wilmington, CA, 2Relapsing Polychondritis Foundation, New York, NY

    Background/Purpose: In 2013, I was diagnosed with Relapsing Polychondritis ("RP"), a systemic inflammatory disease of unknown etiology that can be fatal. The disease affects multiple…
  • « Previous Page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology